Skip to main content

EQT Life Sciences — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$4.5B
Total invested
$72.3M
Avg. check
20
Industries
Health Care 20Biotechnology 17Pharmaceutical 7Therapeutics 7Life Science 6Medical 6+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 81
Cyted
August 2025

Cyted uses artificial intelligence (AI) and digital pathology to improve the detection and diagnosis of diseases, including cancer.

Artificial Intelligence (AI) · Cambridge$44.0M Series B
SNIPR Biome
August 2025

SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.

Biometrics · Copenhagen$40.9M Series B
Splice Bio
June 2025

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

Biotechnology · Barcelona$135.0M Series B
Mosanna Therapeutics
June 2025

Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.

Biotechnology · Redwood City$80.0M Series A
Xilis
April 2025

Xilis is an oncology and precision health company that provides technologies to diagnoses cancer.

Biotechnology · Durham$19.4M Series Unknown
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Perfuze
March 2025

Perfuze is a medical device company developing catheter-based aspiration technology to treat acute ischemic stroke.

Health Care · Newcastle$23.9M Series Unknown
DNA Script
February 2025

DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.

Biotechnology · Le Kremlin-bicêtre$4.7M Grant
Atalanta Therapeutics
January 2025

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

Biotechnology · Boston$97.0M Series B
XyloCor Therapeutics
January 2025

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

Biotechnology · King Of Prussia$67.5M Series B
NUA Surgical
December 2024

NUA Surgical develops a specialised surgical retractor to make C-Sections a safer and superior surgery.

Cosmetic Surgery · Galway$6.9M Series A
ATB Therapeutics
November 2024

ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

Biotechnology · Aye$57.2M Series A
AgomAb Therapeutics
October 2024

Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.

Biotechnology · Antwerpen$88.7M Series D
AviadoBio
October 2024

AviadoBio transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies

Biotechnology · London$20.0M Corporate Round
PanTera
September 2024

PanTera produces actinium-225 for personalized cancer treatment and radiopharmaceuticals.

Health Care · Mol$110.3M Series A
ImCheck Therapeutics
August 2024

ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.

Biopharma · Marseille$22.4M Grant
Shinobi Therapeutics
August 2024

Shinobi Therapeutics is a biotech company that develops immune-evasive iPS cell therapies for cancer treatment.

Biotechnology · South San Francisco$68.0M Series A
Vico Therapeutics
June 2024

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health Care · Leiden$12.3M Series B
Nouscom
March 2024

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

Biotechnology · Basel$7.6M Series C
Onera Health
January 2024

Onera Health is a global leader in sleep diagnostics and monitoring.

Health Care · Eindhoven$32.6M Series C
LUMA Vision
December 2023

LUMA Vision develops a 4D imaging and navigation end-to-end platform for cardiac applications, focusing on point-of-therapy data delivery.

Health Care · Harold's Cross$21.8M Series A
Minervax
October 2023

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

Biotechnology · Hellerup$57.4M Series Unknown
AstronauTx
October 2023

AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.

Biotechnology · Reading$58.7M Series A
QurAlis
March 2023

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

Biotechnology · Cambridge$88.0M Series B

Where EQT Life Sciences invests

Health Care20
Biotechnology17
Pharmaceutical7
Therapeutics7
Life Science6
Medical6

About EQT Life Sciences's portfolio

How many companies has EQT Life Sciences invested in?

EQT Life Sciences has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does EQT Life Sciences invest in?

EQT Life Sciences's top investment sectors include Health Care, Biotechnology, Pharmaceutical, Therapeutics, Life Science. The firm invests across 20 different industry categories.

What is EQT Life Sciences's largest investment?

Among tracked funding rounds, Splice Bio received $135.0M in a Series B round. EQT Life Sciences's total known invested capital is $4.5B.

What is the average investment size for EQT Life Sciences?

EQT Life Sciences's average investment size is $72.3M across its portfolio of 81 companies.

What are EQT Life Sciences's most recent investments?

Recent EQT Life Sciences portfolio additions include Cyted, SNIPR Biome, Splice Bio, Mosanna Therapeutics, Xilis. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →